Biblio
Incidence of blast phase in myelofibrosis according to anemia severity. EJHaem. 2023;4(3):679-689.
RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA. Hematol Oncol. 2020.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2019.
Second cancers in MPN: survival analysis from an international study. Am J Hematol. 2019.